Damora Therapeutics, Inc. (DMRA) stock intrinsic value fair value estimate & owner earnings analysis

Damora Therapeutics (the company was known as Galecto, Inc. until late 2025) is a clinical-stage biotechnology company built around a new antibody program targeting mutant calreticulin (CALR), a protein defect that drives a group of blood-marrow disorders called myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis. The company's earlier pulmonary-fibrosis programs, run under the Galecto name, did not pan out. In November-December 2025 the company acquired rights to the current antibody programs from Paragon Therapeutics and raised approximately $285 million through a private placement of convertible preferred stock, alongside a large new issuance of common stock. The business being valued today is effectively a fresh start: about $540 million in cash, no debt, and a lead candidate, DMR-001, that has shown encouraging potency and half-life results in laboratory and animal studies compared with a competing antibody in development elsewhere, but that has not yet been tested in a single human being. Management has said it plans to file the paperwork to begin human testing of DMR-001 in mid-2026, a second candidate (DMR-002) in the second half of 2026, and a third (DMR-003) in 2027. Because none of the three candidates has any human clinical data yet, this valuation does not credit any value for eventual drug approval or product sales -- that outcome has not happened and cannot be pointed to in what the company has filed. What can be valued is the cash on hand and the pace the company is committed to spending it at pursuing its own stated plan. Spending on research roughly doubled in the first half of 2026 versus all of 2025 as the company staffed up for its first trials, and management has said existing cash (before the $285 million raise) was expected to last into Phase 3 testing of DMR-001 -- a stage that typically arrives only after several years and the bulk of a biotech's cash. Bear case: all three candidates advance in parallel as currently planned, annual spending climbs toward roughly $180 million within five years, and by the time Phase 3 funding would be needed, essentially all of today's cash is gone with nothing provable to show for it. On these assumptions the shares are worth about $(1.45) -- more cash would need to be raised, diluting current holders, before any value could be realized. Base case: the company executes its stated plan for the three candidates at a somewhat more moderate pace (spending rising from roughly $115 million to $150 million a year over five years, in line with the current run-rate and the company's own disclosed filing schedule). Even here, cumulative spending over the visible planning horizon roughly consumes the cash on hand, leaving the shares worth approximately breakeven, around $(0.36). Bull case: the company holds spending somewhat more disciplined while still meeting its own filing timeline, preserving more of the cash cushion. On this path the shares are worth approximately $0.73. These figures will likely look low next to wherever the stock trades, and that gap is intentional. It is the difference between what can be proven today -- a well-funded company with no debt, spending cash on an unproven antibody -- and what the market is paying for the chance that the drug works. That optimism may prove justified, but it is not something we can price without human trial data to point to. Our estimates treat positive early clinical results as the precondition for counting any part of the drug's potential as real value rather than a hope.